Spravato (Esketamine)
Spravato (esketamine) represents a groundbreaking advancement in the treatment of depression. FDA-approved for treatment-resistant depression and major depressive disorder with suicidal ideation, Spravato offers rapid, meaningful symptom relief for patients who have not responded to traditional antidepressant therapies.
FDA-Approved Treatment
Spravato is fully FDA-approved for treatment-resistant depression and major depressive disorder with active suicidal ideation.
Supervised Clinical Setting
Spravato is self-administered as a nasal spray and supervised directly by Dr. Askari in a certified clinical environment.
Targets the Glutamate System
​Unlike traditional antidepressants, Spravato works on the brain's glutamate system, producing faster and more direct symptom relief.
Rapid Symptom Relief
​Many patients experience meaningful reduction in depressive symptoms within hours to days of beginning Spravato treatment.
Frequently Asked Questions
Learn more about Spravato (Esketamine) treatments
What is Spravato and how is it different from traditional antidepressants?
Spravato (esketamine) is an FDA-approved nasal spray that targets the brain's glutamate system, unlike traditional antidepressants which work on serotonin or norepinephrine. This distinct mechanism allows it to work significantly faster, often providing relief within hours to days rather than weeks.
Who is a candidate for Spravato?
​Spravato may be appropriate for adults with treatment-resistant depression who have not responded adequately to at least two antidepressant treatments, or for those experiencing major depressive disorder with active suicidal ideation. Dr. Askari conducts a thorough evaluation to determine if Spravato is right for you.
How is Spravato administered?
Spravato is self-administered as a nasal spray in a certified clinical setting under Dr. Askari's direct supervision. Patients are monitored for approximately two hours following each session before being cleared to leave. You will need to arrange transportation home after each appointment.
How often will I need to come in for Spravato treatments?
Treatment typically begins with two sessions per week for the first four weeks, followed by once weekly for the next four weeks, then tapering to once weekly or once every two weeks as a maintenance dose. Dr. Askari will tailor the schedule to your individual response and needs.
How quickly will I feel the effects of Spravato?
Many patients report a noticeable reduction in depressive symptoms within hours to days of their first session. However, individual responses vary, and the full therapeutic benefit typically becomes more apparent over the course of the initial treatment period.
Are there any side effects I should be aware of?
Common side effects include dissociation, dizziness, nausea, and sedation, which is why supervised administration in a clinical setting is required. These effects are typically temporary and resolve within the monitoring period. Dr. Askari will review your complete medical history to assess any individual risk factors prior to beginning treatment.
Is Spravato covered by insurance?
Spravato is covered by many insurance plans, including Medicare and Medicaid, for patients who meet the clinical criteria. Our team will work with you to verify your coverage and discuss any out-of-pocket costs prior to beginning treatment.
​Is Spravato available via telepsychiatry?
Because Spravato must be administered and monitored in a certified clinical setting, it is not available via telepsychiatry. Patients are required to attend each session in person at our clinic. However, consultations to determine candidacy and follow-up care discussions can be conducted via telepsychiatry where appropriate.
You deserve care that truly understands you. Join Askari Psychiatry today.